Managing the Silent Killer of Businesses: How to Transition A Business Successfully Across Its Lifecycle - Tapa dura

Reseña del editor

The average business in the U.S. has a life expectancy lower than people living in poverty in sub-Saharan Africa. The tragedy is that the suffering and premature death from the silent killers of businesses is preventable with the right diagnostics and strategies.

The tools included in this book help managers know when to stay the strategic course and when and how to change direction. The closest thing to a crystal ball in business will be yours from the:

· self-assessments

· knowledge of lifecycle analysis and

· strategies tailored to transition and succeed in each lifecycle stage.

You'll anticipate changes in markets and competitive behaviors and know what actions should – and shouldn't – be taken. Whether for your business, investment portfolio or career, after reading this book, you'll find more valuable insights and opportunities in each day's news.

To make lifecycle analysis even more powerful, we've included a simple copyrighted seven step validation method. Case studies based on extensive research on scores of firms drawn from dozens of industries provide real world examples with loads of graphs and tables using actual data.

Imagine when you put lifecycle analysis to work for you:

· Joining the organization where your career can soar;

· Building a team of top performers;

· Choosing the right business partners;

· Recognizing if a competitor poses a serious threat;

· Knowing when to buy and when to sell; and

· Hitting your financial targets consistently;

Start leading your business and career to a long and prosperous life.

Biografía del autor

Dr Richard M. Simon is chief of the Biometric Research Branch of the National Cancer Institute, where he is chief statistician for the Division of Cancer Treatment and Diagnosis. He is the lead author of the textbook Design and Analysis of DNA Microarray Experiments and has more than 450 publications. Simon has been influential in promoting excellence in clinical trial design and analysis. He has served on the Oncologic Advisory Committee of the US Food and Drug Administration and is a frequent advisor to government, academic and industry organizations involved with developing improved treatments and diagnostics for patients with cancer. In 1998 Dr Simon established the Molecular Statistics and Bioinformatics Section of the National Cancer Institute, a multidisciplinary group of scientists developing and applying methods for the application of genomics to cancer therapeutics. He is the architect of BRB-ArrayTools software for the analysis of microarray expression and copy number data.